4.8 Article

The cell cycle regulator 14-3-3σ opposes and reverses cancer metabolic reprogramming

期刊

NATURE COMMUNICATIONS
卷 6, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms8530

关键词

-

资金

  1. National Institutes of Health through The University of Texas MD Anderson Cancer Center's Support Grant [CA016672]
  2. National Cancer Institute [RO1CA 089266]
  3. Fidelity Foundation
  4. Directed Medical Research Programs Department of Defense Synergistic Idea Development Award [BC062166]
  5. Susan G. Komen Breast Cancer Research Foundation Promise Grant
  6. CPRIT grant [RP101243-P5]
  7. Vietnam Education Foundation
  8. Rosalie B. Hite Foundation
  9. Department of Defense Breast Cancer Research Program [W81XWH-10-0171]
  10. MD Anderson Cancer Center Training Grant Program in Molecular Genetics [NIH T32CA009299]
  11. cancer prevention fellowship [NIH R25T CA57730]
  12. National Cancer Institute grant minority supplement [NIH R01CA089266]

向作者/读者索取更多资源

Extensive reprogramming of cellular energy metabolism is a hallmark of cancer. Despite its importance, the molecular mechanism controlling this tumour metabolic shift remains not fully understood. Here we show that 14-3-3 sigma regulates cancer metabolic reprogramming and protects cells from tumorigenic transformation. 14-3-3 sigma opposes tumour-promoting metabolic programmes by enhancing c-Myc poly-ubiquitination and subsequent degradation. 14-3-3 sigma demonstrates the suppressive impact on cancer glycolysis, glutaminolysis, mitochondrial biogenesis and other major metabolic processes of tumours. Importantly, 14-3-3 sigma expression levels predict overall and recurrence-free survival rates, tumour glucose uptake and metabolic gene expression in breast cancer patients. Thus, these results highlight that 14-3-3 sigma is an important regulator of tumour metabolism, and loss of 14-3-3 sigma expression is critical for cancer metabolic reprogramming. We anticipate that pharmacologically elevating the function of 14-3-3 sigma in tumours could be a promising direction for targeted anticancer metabolism therapy development in future.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据